Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations

5 days ago · Spero Therapeutics (NASDAQ:SPRO) Third Quarter 2024 ResultsKey Financial Results. Revenue: US$13.5m (down 47% from 3Q 2023). Net loss: US$17.1m (loss widened …

CouponFollow Extension

47%
OFF

Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations

6 days from now

5 days ago · Spero Therapeutics (NASDAQ:SPRO) Third Quarter 2024 ResultsKey Financial Results. Revenue: US$13.5m (down 47% from 3Q 2023). Net loss: US$17.1m (loss widened …

yahoo.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating

6 days from now

Third quarter 2024 Financial Results . Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September 30, 2024, …

nasdaq.com

$10
OFF

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 …

6 days from now

Nov 13, 2024 · In the previous quarter of June 30, 2024, Spero Therapeutics Inc's (NASDAQ:SPRO) actual revenue was $10.2 million, which beat analysts' revenue …

yahoo.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating …

6 days from now

Nov 14, 2024 · Third quarter 2024 Financial Results . Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended …

marketscreener.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating …

6 days from now

Nov 14, 2024 · Spero Therapeutics (SPRO) reported Q3 2024 financial results with a net loss of $17.1 million ($0.32 per share), compared to $3.2 million loss in Q3 2023. Revenue decreased …

stocktitan.net

$7.67
OFF

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 …

6 days from now

Spero Therapeutics Inc (SPRO, Financial) is set to release its Q3 2024 earnings on Nov 14, 2024. The consensus estimate for Q3 2024 revenue is $7.67 million, and the earnings are expected …

gurufocus.com

22%
OFF

Spero Therapeutics's Earnings Outlook - Benzinga

6 days from now

Nov 13, 2024 · Last quarter the company beat EPS by $0.05, which was followed by a 5.22% drop in the share price the next day. ... Quarter Q2 2024 Q1 2024 Q4 2023 Q3 2023; EPS …

benzinga.com

275%
OFF

Spero Therapeutics Second Quarter 2024 Earnings: Beats …

6 days from now

Aug 7, 2024 · Spero Therapeutics (NASDAQ:SPRO) Second Quarter 2024 ResultsKey Financial Results. Revenue: US$10.2m (up 275% from 2Q 2023). Net loss: US$17.9m (loss widened by …

yahoo.com

60%
OFF

Corcept Shares Rise More Than 60% In Three Months: Here's Why

6 days from now

18 hours ago · In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Loss per share estimates for 2025 have narrowed from $1.54 to …

nasdaq.com

$0.10
OFF

Here's What Wall Street Expects From Spero Therapeutics's …

6 days from now

Mar 12, 2024 · On March 13, Spero Therapeutics will be reporting latest earnings. 3 analysts are estimating losses of $0.100 per share as opposed to earnings of $0.550 per share in the same …

businessinsider.com

13%
OFF

TG Therapeutics Stock Crashes After Briumvi Misses 'Whisper ...

6 days from now

Nov 4, 2024 · However, "implied fourth-quarter guidance suggests that quarter-over-quarter growth could range from 13% to 19%," DiFiore said. For the year, TG Therapeutics now …

investors.com

$1.93
OFF

Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations

6 days from now

5 days ago · Marker Therapeutics (NASDAQ:MRKR) Third Quarter 2024 ResultsKey Financial Results. Revenue: US$1.93m (up by US$1.67m from 3Q 2023). Net loss: US$2.31m (loss …

yahoo.com

17%
OFF

Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats …

6 days from now

5 days ago · Vivos Therapeutics (NASDAQ:VVOS) Third Quarter 2024 Results Key Financial Results. Revenue: US$3.86m (up 17% from 3Q 2023). Net loss: US$2.62m (loss widened by …

yahoo.com

FAQs about Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations Coupon?

How did Spero Therapeutics Inc's (Spro) earnings compare to analysts' expectations?

In the previous quarter of June 30, 2024, Spero Therapeutics Inc's (NASDAQ:SPRO) actual revenue was $10.2 million, which beat analysts' revenue expectations of $3.27 million by 212.12%. Spero Therapeutics Inc's (NASDAQ:SPRO) actual earnings were -$0.33 per share, which beat analysts' earnings expectations of -$0.38 per share by 13.16%. ...

How did Spero perform in the third quarter of 2024?

The company reported a net loss of $17.1 million for the third quarter of 2024, reflecting increased research and development expenses as it shifts focus to other strategic projects. Financially, Spero recorded total revenues of $13.5 million for the third quarter, driven by grant and collaboration revenues. ...

How did Spero Therapeutics Inc (Spro) perform in one day?

Spero Therapeutics Inc's (NASDAQ:SPRO) actual earnings were -$0.33 per share, which beat analysts' earnings expectations of -$0.38 per share by 13.16%. After releasing the results, Spero Therapeutics Inc (NASDAQ:SPRO) was down by -5.22% in one day. ...

What is the target price for Spero Therapeutics Inc (Spro)?

After releasing the results, Spero Therapeutics Inc (NASDAQ:SPRO) was down by -5.22% in one day. Based on the one-year price targets offered by 2 analysts, the average target price for Spero Therapeutics Inc (NASDAQ:SPRO) is $5 with a high estimate of $5 and a low estimate of $5. ...

Who is Spero Therapeutics?

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multi-drug resistant bacterial infections. ...

Is 2024 a good year for Spero?

“We look forward to another productive year for Spero in 2024, having achieved important clinical and regulatory milestones over the past twelve months,” said Sath Shukla, President, and CEO of Spero Therapeutics. ...